Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer

Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer

Summary: Despite modest clinical improvement with anti-vascular endothelial growth factor antibody (AVA) therapy in ovarian cancer, adaptive resistance is ubiquitous and additional options are limited. A dependence on glutamine metabolism, via the enzyme glutaminase (GLS), is a known mechanism of ad...

Full description

Bibliographic Details
Main Authors: Deanna Glassman, Mark S. Kim, Meredith Spradlin, Sunil Badal, Mana Taki, Pratip Bhattacharya, Prasanta Dutta, Charles V. Kingsley, Katherine I. Foster, Olamide Animasahun, Jin Heon Jeon, Abhinav Achreja, Anusha Jayaraman, Praveen Kumar, Minal Nenwani, Fulei Wuchu, Emine Bayraktar, Yutuan Wu, Elaine Stur, Lingegowda Mangala, Sanghoon Lee, Timothy A. Yap, Shannon N. Westin, Livia S. Eberlin, Deepak Nagrath, Anil K. Sood
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:iScience
Subjects:
Oncology
Cellular physiology
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004223000974

Internet

http://www.sciencedirect.com/science/article/pii/S2589004223000974

Similar Items